|
Cantor
|
| |
H.C. Wainwright & Co.
|
|
| | |
Page
|
| |||
招股说明书副刊
|
| | | | | | |
关于本招股说明书副刊
|
| | | | S-1 | | |
前瞻性陈述
|
| | | | S-2 | | |
Summary
|
| | | | S-4 | | |
The Offering
|
| | | | S-6 | | |
Risk Factors
|
| | | | S-7 | | |
Use of Proceeds
|
| | | | S-13 | | |
Dividend Policy
|
| | | | S-13 | | |
Dilution
|
| | | | S-14 | | |
美国联邦所得税对非美国持有者的重大后果
|
| | | | S-15 | | |
Plan of Distribution
|
| | | | S-19 | | |
Legal Matters
|
| | | | S-20 | | |
Experts
|
| | | | S-20 | | |
在哪里可以找到更多信息
|
| | | | S-20 | | |
引用合并的信息
|
| | | | S-21 | | |
|
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
|
AGILE THERAPEUTICS, INC
|
| | | | 2 | | |
|
前瞻性陈述
|
| | | | 3 | | |
|
RISK FACTORS
|
| | | | 3 | | |
|
USE OF PROCEEDS
|
| | | | 3 | | |
|
股本说明
|
| | | | 4 | | |
|
认股权证说明
|
| | | | 7 | | |
|
债务证券说明
|
| | | | 9 | | |
|
DESCRIPTION OF RIGHTS
|
| | | | 16 | | |
|
DESCRIPTION OF UNITS
|
| | | | 17 | | |
|
PLAN OF DISTRIBUTION
|
| | | | 18 | | |
|
LEGAL MATTERS
|
| | | | 20 | | |
|
EXPERTS
|
| | | | 20 | | |
|
在哪里可以找到更多信息
|
| | | | 20 | | |
|
通过引用并入的信息
|
| | | | 20 | | |
| | | |
假设每股公开发行价
|
| | | | | | | | | $ | 0.45 | | |
| | | |
2021年9月30日每股有形账面净值
|
| | | $ | 0.11 | | | | | | | | |
| | | |
可归因于新投资者购买此次发行股票的每股有形账面净值增加
|
| | | | 0.18 | | | | | | | | |
| | | |
本次发行后调整后的每股有形账面净值
|
| | | | | | | | | | 0.29 | | |
| | | |
此次发行向新投资者每股摊薄
|
| | | | | | | | | $ | 0.16 | | |
|
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
|
AGILE THERAPEUTICS, INC
|
| | | | 2 | | |
|
前瞻性陈述
|
| | | | 3 | | |
|
RISK FACTORS
|
| | | | 3 | | |
|
USE OF PROCEEDS
|
| | | | 3 | | |
|
股本说明
|
| | | | 4 | | |
|
认股权证说明
|
| | | | 7 | | |
|
债务证券说明
|
| | | | 9 | | |
|
DESCRIPTION OF RIGHTS
|
| | | | 16 | | |
|
DESCRIPTION OF UNITS
|
| | | | 17 | | |
|
PLAN OF DISTRIBUTION
|
| | | | 18 | | |
|
LEGAL MATTERS
|
| | | | 20 | | |
|
EXPERTS
|
| | | | 20 | | |
|
在哪里可以找到更多信息
|
| | | | 20 | | |
|
通过引用并入的信息
|
| | | | 20 | | |